American Heart Journal
Volume 159, Issue 3 , Pages 348-353.e1, March 2010

Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment

Received 12 June 2009; accepted 6 August 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 See Appendix for a complete listing of AVERROES Steering Committee.

 RCT#: NCT00496769.

PII: S0002-8703(09)00947-8

doi:10.1016/j.ahj.2009.08.026

American Heart Journal
Volume 159, Issue 3 , Pages 348-353.e1, March 2010

Article Tools

* Image Usage & Resolution